In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Mar 1 2010|
- Atypical antipsychotic
- Generic penetration
ASJC Scopus subject areas
- Psychiatry and Mental health